Bcr/abl融合基因在慢性粒细胞白血病中的检测方法及意义(4)
第1页 |
参见附件。
[14]Branford S KD-W, Soverini S, et al. Molecular response at 3 months on Nilotinib therapy predicts response and long-term outcomes in patients with Imatinib-resistant or intolerant chronic myeloid leukemia in chronic phase(CML-CP)[J]. Presented at: 51st Annual Meeting of American Society of Hematology New Orleans, LA, USA,5-8, December 2009.
[15]江浩,黄晓军.慢性髓性白血病临床诊疗指南与中国实践[J].中国实用内科杂志,2010,30(1):32-34.
[16]黄晓军.中国慢性髓性白血病的治疗方案选择[J].中国实用内科杂志,2008,11(28):927-929.
[17]许兰平,刘开彦,黄晓军,等 ......
您现在查看是摘要介绍页,详见PDF附件。